Data on cholesterol drug fenofibrate lead to FDA advisory

11/9/2011 | Medscape (free registration)

Data from the ACCORD Lipid trial showed the cholesterol-lowering drug fenofibric acid or fenofibrate may not reduce the risk of major cardiovascular events, leading the FDA to issue a safety communication and update prescribing information. The agency also asked for a trial to study the medication's cardiovascular effects in patients on statins.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN